Longevity Health Holdings Announces Business Updates

Core Insights - Longevity Health Holdings, Inc. (XAGE) focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [2] - The company announced a merger agreement with 20/20 BioLabs, which will continue as a wholly owned subsidiary post-merger [4] Business Updates - 20/20 develops laboratory tests for early detection and management of chronic disease risk, including a multi-cancer early detection blood test and a new blood test for monitoring chronic inflammation [1][4] - XAGE reported Q1 sales of approximately $663,000, an 8% increase year-over-year, while 20/20 reported sales of approximately $562,000, a 15% increase year-over-year [4] - A reverse stock split of 1 for 30 was completed on May 12, 2025, with trading at the adjusted price starting on May 14, 2025 [4] Product Launches - XAGE plans to launch a medicated cleanser for use in physicians' offices and MedSpas, targeting 20/20's customer base [4] - 20/20 is set to launch a lab test measuring inflammatory biomarkers, which will also be marketed to XAGE's customer base [4] - An initiative with Giant Food will offer 20/20's multi-cancer test in select stores, with potential expansion to include tests for biomarkers linked to pro-inflammatory foods [4] Financial Considerations - XAGE is evaluating options for additional financing and anticipates announcing a primary investment in Q2 2025 [4]